Overview

Phase I PK Comparison of HLX05 vs. Erbitux in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, single intravenous dose, parallel study to compare the PK characteristics, safety, tolerability, and immunogenicity of HLX05 vs. Erbitux (US-, EU-, and CN-sourced) in healthy adult male Chinese subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Henlius Biotech